Abstract
Neoadjuvant treatments for locally advanced lung cancers continue to evolve, and more compelling prospective data are becoming available. Neoadjuvant cytotoxic chemotherapy or radiation for stage I or II disease has not been well supported, with the exception of attempting to downstage tumors before surgical resection.1 Phase II trials established the current standard of care of neoadjuvant chemoradiotherapy followed by surgical resection for superior sulcus tumors, and current guidelines support the role of neoadjuvant treatment for patients with stage IIIA disease, including patients with nonbulky N2 involvement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
